We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

I heard you like SPACs

20 May 2021 By John Foley, Robert Cyran

The biotech firm may raise money from a blank-check company, then buy out a drugmaker it previously merged with a SPAC. It sounds complex, but what Roivant is doing is at heart not so different from any IPO. The catch is that it has inside intel, and an incentive to exploit it.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)